SCHEMBL3241795

SCHEMBL3241795

Cc1ccc(C)c(C(=O)NC(c2ccccc2)C(C)(C)N2CCCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ABCB1 P08183 1/20 0.39
UTS2R Q9UKP6 1/20 0.38
HPGD P15428 1/20 0.38
CACNA2D1 P54289 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNB1 Q02641 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
KCNK3 O14649 2/20 0.37
BRD4 O60885 1/20 0.37
CTSV O60911 1/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238743 0.91 KMT2A (0.45) POLBALDH1A1LMNASMN1; SMN2UTS2R
SCHEMBL3230747 0.87 KLRK1 (0.44) KCNK3
SCHEMBL3233194 0.84 CNR1 (0.40) ALDH1A1LMNASMN1; SMN2HPGDCNR1
SCHEMBL3233025 0.84 SLC6A9 (0.39) ALDH1A1LMNASMN1; SMN2HPGDCACNA2D1
SCHEMBL3237083 0.83 POLB (0.42) POLBALDH1A1LMNASMN1; SMN2ABCB1
SCHEMBL3235817 0.83 TAS1R3 (0.41) ALDH1A1HPGDCNR2KCNK3
SCHEMBL3243734 0.81 SLC6A9 (0.48) ALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL3238470 0.81 SLC6A9 (0.46) ALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL3245881 0.81 SLC6A9 (0.39) ALDH1A1LMNASMN1; SMN2HPGD
SCHEMBL3238301 0.80 SLC6A9 (0.47) POLBALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
WO-2006067423-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 POLB 2897/4885ALDH1A1 1356/4885LMNA 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.